← Leaderboards
Matthew A. Spinelli
University Of California, San Francisco
$5,669,060
Attributed
$10,015,319
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,015,319 · 6
By mechanism
R01$4,705,301 · 2
UG3$2,024,874 · 1
UH3$1,828,735 · 1
K23$1,012,284 · 1
R21$444,125 · 1
Top collaborators
- Monica Gandhi9 shared
- Adam Wayne Carrico3 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Rebecca L Sudore$11,687,748
- Monica Gandhi$27,077,063
- Margot B Kushel$15,430,352
- Janet Yi Man Lee$609,179
- Adam Wayne Carrico$20,345,043
Others in their field
Other Emerging Leaders on “Cohort”
- Leonard Freedman · Leidos Biomedical Research, Inc.$70,225,348
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Julie Ake · National Institute Of Allergy And Infectious Diseases$52,642,120
- Sarah Fortune · Harvard School Of Public Health$51,119,645
- Scott Hensley · University Of Pennsylvania$47,346,110
- Susan M Landau · University Of California Berkeley$47,252,026
Research focus
CohortPharmaceutical PreparationsAdherenceEpidemicTenofovirVisitReportingFutureParticipantHiv InfectionsIncidenceClinicProviderPersonsAnti-Retroviral AgentsPublic HealthUrineHairRecruitSamplingPoint Of CareCostRandomizedHealth System
Grant awards (16)
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.$1,828,735
UH3 · FY2025 · DA · contact PI
Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP$813,232
R01 · FY2025 · AI · contact PI
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.$970,487
UG3 · FY2024 · DA · contact PI
Randomized Directly Observed Therapy Study to Interpret Clinical Trials of Doxy-PEP$781,821
R01 · FY2024 · AI · contact PI
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)$183,456
K23 · FY2024 · MH · contact PI
Developing a U.S. National Cohort to Improve Virologic Suppression among Stimulant-using Men Living with HIV.$1,054,387
UG3 · FY2023 · DA · contact PI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic$798,527
R01 · FY2023 · AI
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines$242,250
R21 · FY2023 · AI
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)$197,028
K23 · FY2023 · MH · contact PI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic$802,565
R01 · FY2022 · AI
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)$210,600
K23 · FY2022 · MH · contact PI
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines$201,875
R21 · FY2022 · AI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic$799,372
R01 · FY2021 · AI
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)$210,600
K23 · FY2021 · MH · contact PI
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic$709,784
R01 · FY2020 · AI
PrEP Point-of-Care Brief-Intervention for Adherence among Young Men Who Have Sex with Men (PrEP2-BAY Study)$210,600
K23 · FY2020 · MH · contact PI